Myriad Genetics, Inc. (NASDAQ:MYGN) VP Gary A. King sold 3,120 shares of the company’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $38.12, for a total transaction of $118,934.40. Following the completion of the sale, the vice president now owns 125,088 shares of the company’s stock, valued at approximately $4,768,354.56. The transaction was disclosed in a filing with the SEC, which is available through this link.

Myriad Genetics, Inc. (MYGN) traded up $1.15 on Friday, reaching $37.99. 1,030,600 shares of the company traded hands, compared to its average volume of 645,542. The company has a market capitalization of $2,640.00, a price-to-earnings ratio of 25.67, a P/E/G ratio of 2.34 and a beta of 0.24. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $38.27.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.05. The company had revenue of $190.20 million during the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.23 earnings per share. equities analysts predict that Myriad Genetics, Inc. will post 1.05 EPS for the current year.

Several analysts have recently issued reports on MYGN shares. Zacks Investment Research lowered shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 15th. ValuEngine lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Morgan Stanley upped their target price on shares of Myriad Genetics from $24.00 to $26.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 8th. Deutsche Bank upped their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, November 8th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $31.00 target price on shares of Myriad Genetics in a research note on Monday, October 2nd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $30.09.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in Myriad Genetics during the second quarter valued at about $101,000. Riverhead Capital Management LLC lifted its holdings in Myriad Genetics by 80.9% during the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after purchasing an additional 1,861 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in Myriad Genetics by 1,067.4% during the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after purchasing an additional 3,010 shares during the last quarter. Tiedemann Wealth Management LLC lifted its holdings in Myriad Genetics by 67.0% during the third quarter. Tiedemann Wealth Management LLC now owns 13,650 shares of the company’s stock valued at $185,000 after purchasing an additional 5,475 shares during the last quarter. Finally, Commonwealth Equity Services Inc purchased a new stake in Myriad Genetics during the third quarter valued at about $202,000.

TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/myriad-genetics-inc-mygn-vp-sells-3120-shares-of-stock.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.